Assessing cabozantinib with PARP inhibitors in DDR mutant-tumors

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid TumorsПодробнее

Discussing Targeted Treatment With PARP Inhibitors for BRCA-Mutant Patients Across Tumor TypesПодробнее

Investigating the ATR inhibitor elimusertib in advanced solid tumorsПодробнее

Developing novel therapeutic strategies to target DNA damage responseПодробнее

Targeted cancer therapy: choosing the right assay to assess PARP inhibitorsПодробнее

Targeting the DNA damage response in gynaecological cancers beyond PARP inhibitors - Dr. Yvette DrewПодробнее

The Role of Targeting DNA Repair with PARPПодробнее

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumoursПодробнее

Niraparib in BAP1 and DDR pathway deficient solid tumorsПодробнее

Chad Creighton - A PBTA of Genes Deregulated by Somatic Genomic RearrangementПодробнее

Two Drugs Targeting DNA Damage Response Show Promise in Ongoing Cancer TrialsПодробнее

WHAT IS THE SUCCESS RATE OF DDR INHIBITORS IN TREATING MESOTHELIOMA?Подробнее

DNA Repair: PARP, A Target in EvolutionПодробнее

DNA Damage ResponseПодробнее

Dr. Sessa Discusses ATR Inhibitors in BRCA-Mutated TumorsПодробнее

Cabozantinib demonstrates disease control in advanced adrenocortical carcinomaПодробнее

PARP InhibitorsПодробнее

💊 Unlocking Synthetic Lethality: Targeting PARP Inhibition in BRCA1 and BRCA2 Mutant Cancers 🛑Подробнее

Use of PARP1-selective and ATR inhibitors to target DDR signalling pathwayПодробнее